Herein, we report a case of an EGFR-mutated lung adenocarcinoma patient who developed refractory dyspnea and hypoxemia after 1.5 months of osimertinib therapy, ultimately leading to treatment failure and death. This evidence concerns the gene EGFR and lung adenocarcinoma.